Bivalirudin use during radiofrequency catheter ablation procedures in two patients with a history of heparin-induced thrombocytopenia

Current guidelines recommend using bivalirudin, a direct thrombin inhibitor,as a preferred alternative to unfractionated heparin in patients with heparin induced thrombocytopenia (HIT) for percutaneous coronary intervention, as well as for cardiac and vascular surgery. Anticoagulation during radiofrequency catheter ablation (RFA) procedures may be another potential use for bivalirudin in the setting of HIT. Radiofrequency catheter ablation procedures involving left atrial or left ventricular access are increasingly employed as a method to treat cardiac arrhythmias. Because stroke risk is a serious complication of RFA, anticoagulation is required during this procedure. We describe the first report, to our knowledge, of successful use of bivalirudin anticoagulation during RFA procedures in two patients with a history of clinically diagnosed HIT that precluded the use of unfractionated heparin or low-molecular-weight heparin. One of the patients underwent RFA for ventricular tachycardia, the other for pulmonary vein isolation for the treatment of atrial fibrillation. In both patients, bivalirudin was administered as a 0.75-mg/kg intravenous bolus, followed by a 1.75-mg/kg/hour infusion.Activated clotting time (ACT) was measured after the initial bolus in each patient. However, no dosage adjustment was made based on the ACT, and the infusion rate of bivalirudin remained fixed during the procedures. Both procedures were completed without any embolic events. No bleeding or clotting events were noted; one patient experienced minor access site oozing that was not felt to be clinically important. Bivalirudin is a therapeutic option for anticoagulation during left-sided catheter RFA procedures in patients with a history of HIT.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

First reported use of bivalirudin anticoagulation during radiofrequency catheter ablation in two HIT-history patients undergoing ventricular tachycardia and atrial fibrillation procedures, both completed without embolic or bleeding events.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Explore how this research connects to clinical practice

More peer-reviewed studies in Clinical Trials.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
• Reverse Sural Flap Venous Congestion Successfully Managed With Enoxaparin in a Male Patient With a Traumatic Foot Crush Injury: A Case Report — Velasco-Bustamante J et al. (2026)
• Investigation of the therapeutic effects of medicinal leech treatment on lower extremity ischemia-reperfusion injury — Ünal K et al. (2026)
• Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan — Farzali S et al. (2025)
• HIRUDOTHERAPY IN RECONSTRUCTIVE SURGERY: CASE-REPORTS AND REVIEW — Heinz P et al. (2020)
• Hirudotherapy Efficacy and Complications in the Management of Microsurgical Breast Reconstruction: A Systematic Review — Foppiani J et al. (2024)
• Hirudotherapy in Wound Healing — Nair H et al. (2022)

Browse all ASH-analysed research →